We are likely just six weeks away from the R&D day as the time flies. The RRP data is expected to be presented there, so it's not too long of a wait now. I personally would be very surprised to see earth-shattering data as this is an open label trial and those in-the-know do some data-mining and have a good knowledge of how the trial is going, how the patients react to the treatment, how the frequency of the surgeries changed and what approximate percentage of response rate is. Do they know it all? No, but much better than the retail. If the data is super great, then it would have been reflected in the share price. $3-$4 range would have been shattered long time ago and we might be closer to 8 or 9 than to $2 now. Based on the strength of the stock (or, the lack of thereof) I'd have to assume the data is not too bad, but not strong enough to bypass a large Ph3 trial to get an approval. And that's big $$$ and time. This is my take.
PS. I have been wrong too many times and hope to be correct the first time.